Scripps Cancer Center's 40th Annual Conference: Clinical Hematology & Oncology 2020


 

PI3K Inhibitors Are Highly Active in R/R Follicular Lymphoma, New Dosing Strategies May Improve Tolerance Without Sacrificing Efficacy

115 views
March 4, 2020
0 Comments
Login to view comments. Click here to Login
Malignant Hematology